创新药概念震荡回升，海思科逼近涨停创历史新高

Group 1 - The innovative drug concept is experiencing a rebound, with companies like Haikang Science nearing a trading limit and reaching historical highs in stock prices [1] - Several companies, including Shouyao Holdings, Zhaoyan New Drug, Medisi, Changshan Pharmaceutical, Kailaiying, and Dizhe Pharmaceutical, have seen stock price increases of over 5% [1] - On August 12, the National Healthcare Security Administration announced the preliminary review results for the 2025 medical insurance catalog and commercial insurance innovative drug catalog, with 534 drugs passing the basic medical insurance catalog review and 121 drug generic names passing the commercial insurance innovative drug catalog review [1] Group 2 - High-priced innovative drugs, including the CAR-T cancer treatment priced in the millions, are pushing for inclusion in the commercial insurance innovative drug catalog, seeking new payment avenues for innovative drugs [1]